Drug General Information (ID: DDI1BIQ9ZW)
Drug Name			Alemtuzumab		Drug Info		Rubella virus vaccine		Drug Info
Drug Type		Monoclonal antibody				Vaccine
Therapeutic Class		Antineoplastics				Vaccine

Mechanism of Alemtuzumab-Rubella virus vaccine Interaction (Severity Level: Major)
Antagonize the effect of vaccine/toxoid Click to Show/Hide Mechanism Graph
Drug Name		Alemtuzumab				Rubella virus vaccine
Mechanism		Immunosuppressive effects				Vaccine or toxoid
Key Mechanism Factor 1
		Factor Name		Vaccine/toxoid
		Factor Description		The beneficial effects of the vaccine/toxinoid may be reduced, leading to a diminished or suboptimal immune response.
Mechanism Description		Antagonize the effect of Rubella virus vaccine when combined with Alemtuzumab

Recommended Action
Management		In general, live virus or bacterial vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy. Vaccination should be deferred until after such therapy is discontinued for at least 3 months in most cases. In patients who have recently been vaccinated, such therapy should not be initiated for at least 2 weeks.

References
1	CDC. Centers for Disease Control and Prevention/ "Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence." MMWR Morb Mortal Wkly Rep 42(RR-04) (1993): 1-18. [PMID: 20300058]
2	Product Information. Campath (alemtuzumab) Berlex, Richmond, CA.
3	Fauci AS, Braunwald E, Isselbacher KJ, Wilson JD, Martin JB, Kasper DL, Hauser SL, Longo DL, eds. "Harrison's Principles of Internal Medicine. 14th ed." New York, NY: McGraw-Hill Health Professionals Division (1998).